Geoff Race - Apr 28, 2023 Form 4 Insider Report for Minerva Neurosciences, Inc. (NERV)

Role
President
Signature
/s/ Ryan Sansom, Attorney-in-Fact
Stock symbol
NERV
Transactions as of
Apr 28, 2023
Transactions value $
-$85,016
Form type
4
Date filed
5/2/2023, 06:14 PM
Previous filing
Dec 14, 2022
Next filing
Oct 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NERV Common Stock Award $0 +47K +177.85% $0.00 73.4K Apr 28, 2023 Direct F1
transaction NERV Common Stock Sale -$85K -22.1K -30.08% $3.85 51.3K May 1, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs"), representing 50% of the shares underlying the PRSUs. On April 28, 2023, the Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for roluperidone.
F2 The sales reported in this Form 4 represent nondiscretionary sales of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of the PRSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.